[1] National Health Commission of the People's Republic of China. Notice of the General Office of the National Health and Family Planning Commission on adjusting thestandard of freeantiviral treatment for AIDS. https://www.nhc.gov.cn/yzygj/c100068/201606/283ad16303dd4439a6574de60b560db2.shtml. [2024-09-01]. (In Chinese)
[2] Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis, 2011; 11, 363−71. doi:  10.1016/S1473-3099(11)70032-9
[3] Pingarilho M, Pimentel V, Miranda MNS, et al. HIV-1-transmitted drug resistance and transmission clusters in newly diagnosed patients in Portugal between 2014 and 2019. Front Microbiol, 2022; 13, 823208. doi:  10.3389/fmicb.2022.823208
[4] Chen HL, Hao JJ, Hu J, et al. Pretreatment HIV drug resistance and the molecular transmission network among HIV-positive individuals in China in 2022: multicenter observational study. JMIR Public Health Surveill, 2023; 9, e50894. doi:  10.2196/50894
[5] Kityo C, Boerma RS, Sigaloff KCE, et al. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. J Antimicrob Chemother, 2017; 72, 2587−95. doi:  10.1093/jac/dkx188
[6] Zheng XW, Tian CQ, Choi KH, et al. Injecting drug use and HIV infection in southwest China. AIDS, 1994; 8, 1141−7. doi:  10.1097/00002030-199408000-00017
[7] Duan X, Wang MC, Wang YK, et al. Pre-treatment drug resistance mutations of pol gene and related factors in newly reported HIV/AIDS in Dehong Dai and Jingpo Autonomous Prefecture from 2017 to 2019. Chin J Viral Dis, 2022; 12, 343−8. (In Chinese)
[8] Tee KK, Pybus OG, Li XJ, et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol, 2008; 82, 9206−15. doi:  10.1128/JVI.00399-08
[9] Feng Y, He X, Hsi JH, et al. The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s. AIDS, 2013; 27, 1793−802. doi:  10.1097/QAD.0b013e328360db2d
[10] Yang YC, Zhao H, Li L, et al. High-risk behavior survey of 2017-2018 Dehong Dai Jingpo autonomous prefecture newly reported Burmese HIV infected people. Chin J Dis Control Prev, 2020; 24, 1376−81. (In Chinese)
[11] Ding YB, Chen M, Wang JB, et al. Analysis on characteristics of untreated 16-25 years old people living with HIV-1 at the China-Myanmar border from 2009 to 2017 based on molecular network method. Chin J Exp Clin Virol, 2021; 35, 124−9. (In Chinese)
[12] Paraskevis D, Kostaki E, Magiorkinis G, et al. Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003-2015: transmitted drug resistance is due to onward transmissions. Infect Genet Evol, 2017; 54, 183−91. doi:  10.1016/j.meegid.2017.07.003
[13] Bandera A, Gori A, Clerici M, et al. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr Opin Pharmacol, 2019; 48, 24−32. doi:  10.1016/j.coph.2019.03.003
[14] National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. Technical guidelines for HIV transmission network monitoring and intervention (pilot). https://ncaids.chinacdc.cn/zxzx/zxdteff/201909/t20190929_205904.htm. [2024-09-01]. (In Chinese)
[15] Cao P, Guo CY, Feng Y, et al. Research on HIV gene sequence data management and analysis system in China. Chin J AIDS STD, 2023; 29, 848−53. (In Chinese)
[16] Zhang F, Liang BY, Liang X, et al. Using molecular transmission networks to reveal the epidemic of pretreatment HIV-1 drug resistance in Guangxi, China. Front Genet, 2021; 12, 688292. doi:  10.3389/fgene.2021.688292
[17] Kosakovsky Pond SL, Weaver S, Leigh Brown AJ, et al. HIV-TRACE (TRAnsmission Cluster Engine): a tool for large scale molecular epidemiology of HIV-1 and other rapidly evolving pathogens. Mol Biol Evol, 2018; 35, 1812−9. doi:  10.1093/molbev/msy016
[18] Zhou C, Liang S, Li YP, et al. Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China. BMC Infect Dis, 2022; 22, 602. doi:  10.1186/s12879-022-07576-z
[19] Arenas M, Lorenzo-Redondo R, Lopez-Galindez C. Influence of mutation and recombination on HIV-1 in vitro fitness recovery. Mol Phylogenet Evol, 2016; 94, 264−70. doi:  10.1016/j.ympev.2015.09.001
[20] Rawson JMO, Nikolaitchik OA, Keele BF, et al. Recombination is required for efficient HIV-1 replication and the maintenance of viral genome integrity. Nucleic Acids Res, 2018; 46, 10535−45.
[21] Carvajal-Rodríguez A, Crandall KA, Posada D. Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. Infect Genet Evol, 2007; 7, 476−83. doi:  10.1016/j.meegid.2007.02.001
[22] Xuan QC, Liang SW, Qin WH, et al. High prevalence of HIV-1 transmitted drug resistance among therapy-naïve Burmese entering travelers at Dehong ports in Yunnan, China. BMC Infect Dis, 2018; 18, 211. doi:  10.1186/s12879-018-3130-9
[23] The TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis, 2016; 16, 565−75. doi:  10.1016/S1473-3099(15)00536-8
[24] World Health Organization. HIV drug resistance report 2021. https://www.who.int/publications/i/item/9789240038608. [2024-09-01]
[25] Sebastião CS, Abecasis AB, Jandondo D, et al. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola. Sci Rep, 2024; 14, 15893. doi:  10.1038/s41598-024-66905-1
[26] Bissio E, Barbás MG, Bouzas MB, et al. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15. J Antimicrob Chemother, 2017; 72, 504−10. doi:  10.1093/jac/dkw445
[27] Hofstra LM, Nijhuis M, Pingen M, et al. Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients. J Antimicrob Chemother, 2013; 68, 1246−50. doi:  10.1093/jac/dkt038
[28] Ye RH, Liang XY, Cao DD, et al. Beforehand prevention, downward shift of governance focus——Dehong Dai and Jingpo autonomous prefecture took the lead in achieving “Three 90%” AIDS prevention and control targets. China J Prim Health Care, 2022; 36, 70−2,75. (In Chinese)